Molecular imaging of hypoxia with radiolabelled agentsReport as inadecuate

Molecular imaging of hypoxia with radiolabelled agents - Download this document for free, or read online. Document in PDF available to download.

European Journal of Nuclear Medicine and Molecular Imaging

, Volume 36, Issue 10, pp 1674–1686

First Online: 30 June 2009Received: 04 February 2009Accepted: 07 June 2009


Tissue hypoxia results from an inadequate supply of oxygen O2 that compromises biological functions. Structural and functional abnormalities of the tumour vasculature together with altered diffusion conditions inside the tumour seem to be the main causes of tumour hypoxia. Evidence from experimental and clinical studies points to a role for tumour hypoxia in tumour propagation, resistance to therapy and malignant progression. This has led to the development of assays for the detection of hypoxia in patients in order to predict outcome and identify patients with a worse prognosis and-or patients that would benefit from appropriate treatments. A variety of invasive and non-invasive approaches have been developed to measure tumour oxygenation including oxygen-sensitive electrodes and hypoxia marker techniques using various labels that can be detected by different methods such as positron emission tomography PET, single photon emission computed tomography SPECT, magnetic resonance imaging MRI, autoradiography and immunohistochemistry. This review aims to give a detailed overview of non-invasive molecular imaging modalities with radiolabelled PET and SPECT tracers that are available to measure tumour hypoxia.

KeywordsHypoxia PET SPECT Nitroimidazole  Download fulltext PDF

Author: Gilles Mees - Rudi Dierckx - Christel Vangestel - Christophe Van de Wiele


Related documents